NcXHF

ODENIKE, ONIDA, AND PADRON
mendations from the European LeukemiaNet. Blood. 2013;122:2943-
2964.
9. Vaughn JE, Scott BL, Deeg HJ. Transplantation for myelodysplastic
syndromes 2013. Curr Opin Hematol. 2013;20:494-500.
10. Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes:
clinical practice guidelines in oncology. J Natl Compr Cancer Netw.
2013;11:838-874.
11. Ofran Y, Lazarus HM, Rapoport AP, et al. Interpreting outcome data
in hematopoietic cell transplantation for leukemia: tackling common
biases. Bone Marrow Transpl. Epub 2015 Jan 12.
12. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic
syndromes and chronic myeloproliferative disorders in the
United States, 2001-2004, using data from the NAACCR and SEER
programs. Blood. 2008;112:45-52.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classifıcation of
the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
14. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World
Health Organization (WHO) classifıcation of myeloid neoplasms and
acute leukemia: rationale and important changes. Blood. 2009;114:
937-951.
15. Greenberg P, Cox C, LeBeau MM, et al. International scoring system
for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;
89:2079-2088.
16. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic
scoring system for predicting survival and leukemic evolution in
myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510.
17. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model
in myelodysplastic syndrome that accounts for events not considered
in the original International Prognostic Scoring System. Cancer. 2008;
113:1351-1361.
18. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients
with lower risk myelodysplastic syndrome. Leukemia. 2008;22:
538-543.
19. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic
scoring system for myelodysplastic syndromes. Blood. 2012;120:
2454-2465.
20. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic
scoring system for primary myelodysplastic syndromes (MDS) and
oligoblastic acute myeloid leukemia after MDS derived from an international
database merge. J Clin Oncol. 2012;30:820-829.
21. Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic
Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic
syndromes signifıcantly better than IPSS and WHO
Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie
Italian Regional Database. J Clin Oncol. 2013;31:2671-2677.
22. Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised
International Prognostic Scoring System in treated patients with myelodysplastic
syndromes. Am J Hematol. 2013;88:566-570.
23. Breccia M, Salaroli A, Loglisci G, et al. Revised IPSS (IPSS-R) stratifıcation
and outcome of MDS patients treated with azacitidine. Ann Hematol.
2013;92:411-412.
24. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point
mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:
2496-2506.
25. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic
model and the impact of mutations in patients with lower-risk myelodysplastic
syndromes. J Clin Oncol. 2012;30:3376-3382.
26. Odenike O, Le Beau MM. The dawn of the molecular era of the myelodysplastic
syndromes. N Engl J Med. 2011;364:2545-2546.
27. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions
in 944 patients with myelodysplastic syndromes. Leukemia.
2014;28:241-247.
28. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation
in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;
365:1384-1395.
29. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations
of splicing machinery in myelodysplasia. Nature. 2011;478:64-69.
30. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary
acute myeloid leukemia. N Engl J Med. 2012;366:1090-1098.
31. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations
identify distinct disease entities within myeloid neoplasms with
myelodysplasia. Blood. 2014;124:1513-1521.
32. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated
decision model for treating the anaemia of myelodysplastic syndromes
with erythropoietin granulocyte colony-stimulating factor: signifıcant
effects on quality of life. Br J Haematol. 2003;120:1037-1046.
33. Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic
syndromes. JAMA. 2011;305:814-819.
34. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to
predict response to immunosuppressive therapy in patients with myelodysplastic
syndrome. Blood. 2003;102:3025-3027.
35. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow
hypocellularity in MDS patients predict hematological responses to
antithymocyte globulin. Leukemia. 2007;21:1436-1441.
36. Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the
phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone,
and granulocyte colony-stimulating factor in patients
with aplastic anaemia and myelodysplastic syndrome. Br J Haematol.
2012;157:312-320.
37. Komrokji RS, Mailloux AW, Chen DT, et al. A phase II multicenter
rabbit anti-thymocyte globulin trial in patients with myelodysplastic
syndromes identifying a novel model for response prediction. Haematologica.
2014;99:1176-1183.
38. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic
syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:
1456-1465.
39. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in
transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic
syndromes with karyotypes other than deletion 5q. Blood. 2008;
111:86-93.
40. Mallo M, Del Rey M, Ibáňez M, et al. Response to lenalidomide in myelodysplastic
syndromes with del(5q): influence of cytogenetics and
mutations. Br J Haematol. 2013;162:74-86.
41. Komrokji RS, Lancet JE, Swern AS, et al. Combined treatment with
lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic
syndrome. Blood. 2012;120:3419-3424.
42. Fink EC, Krönke J, Hurst S, et al. Lenalidomide induces ubiquitination
and degradation of CSNK1A1 in MDS with Del(5q). Paper presented
at: 56th Annual Meeting of the American Society of Hematology; December
2014; San Francisco, CA.
43. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant
genes. Nat Rev Cancer. 2010;10:23-36.
44. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs
overall survival compared with conventional care regimens in elderly
patients with low bone marrow blast count acute myeloid leukemia.
J Clin Oncol. 2010;28:562-569.
45. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient
outcomes in myelodysplastic syndromes: results of a phase III randomized
study. Cancer. 2006;106:1794-1803.
46. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled
trial of azacitidine in patients with the myelodysplastic syndrome: a
study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-
2440.
47. Wang R, Gross CP, Frick K, et al. The impact of hypomethylating
e408
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook